Study Evaluating Safety, Tolerability, and Metabolism of Niraparib - Trial NCT06412120
Access comprehensive clinical trial information for NCT06412120 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of Miami and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 70 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Miami
Timeline & Enrollment
Phase 4
Sep 01, 2024
Sep 01, 2029
Primary Outcome
Proportion of Participants Experiencing Any Grade or Grade 3 or Higher of the Most Common Adverse Events (AEs) Previously Reported in the PRIMA trial (NCT02655016).
Summary
The purpose of this study is to identify the genetic characteristic(s), specifically degree
 of African ancestry, and environmental characteristic(s) that appear to be related to the
 effects, both good and bad, that the maintenance treatment has women with ovarian cancer. In
 this study, an investigational medication called niraparib is being tested for the treatment
 of ovarian cancer. Niraparib works by blocking the ability of cancer cells to fix their
 genes. Cancer cells with damaged genes have a harder time growing and spreading in the body
 and can even die.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06412120
Non-Device Trial